Compare CACI & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CACI | CORT |
|---|---|---|
| Founded | 1962 | 1998 |
| Country | United States | United States |
| Employees | N/A | 730 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 9.7B |
| IPO Year | 2007 | 2001 |
| Metric | CACI | CORT |
|---|---|---|
| Price | $499.00 | $89.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $689.50 | $96.50 |
| AVG Volume (30 Days) | 267.4K | ★ 957.9K |
| Earning Date | 04-22-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ 17.11 | N/A |
| Revenue | ★ $4,467,860,000.00 | $761,407,000.00 |
| Revenue This Year | $12.42 | $26.08 |
| Revenue Next Year | $10.00 | $26.98 |
| P/E Ratio | $29.35 | ★ N/A |
| Revenue Growth | 2.60 | ★ 12.79 |
| 52 Week Low | $434.70 | $28.66 |
| 52 Week High | $683.50 | $91.00 |
| Indicator | CACI | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 54.98 | 80.68 |
| Support Level | $499.81 | $76.41 |
| Resistance Level | $511.94 | N/A |
| Average True Range (ATR) | 20.24 | 3.76 |
| MACD | 0.61 | -0.09 |
| Stochastic Oscillator | 71.23 | 94.20 |
CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.